Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. | Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer.

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as competition intensifies in the oncology space.

The Rahway, N.J., drug maker said Friday that its treatment, Keytruda, has been approved for adult patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1, a protein that helps to keep the body's immune responses under control.

Merck is establishing a program of clinical trials for V181, including conducting trials globally, in places where dengue is a significant health threat.

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary endpoint readouts as proof that the candidate still deserves a shot at seeking approval.

Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.